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Introduction:While much emphasis on safety in the radiation oncology clinic is placed on
process, there remains considerable opportunity to increase safety, enhance outcomes,
and avoid ad hoc care by instituting detailed treatment pathways. The purpose of this
study was to review the process of developing evidence and consensus-based, outcomes-
oriented treatment pathways that standardize treatment and patient management in a large
multi-center radiation oncology practice. Further, we reviewed our compliance in incorpo-
rating these directives into our day-to-day clinical practice.
Methods: Using the Institute of Medicine guideline for developing treatment pathways,
87 disease specific pathways were developed and incorporated into the electronic med-
ical system in our multi-facility radiation oncology department. Compliance in incorporating
treatment pathways was assessed by mining our electronic medical records (EMR) data
from January 1, 2010 through February 2012 for patients with breast and prostate cancer.
Results:This retrospective analysis of data from EMR found overall compliance to breast
and prostate cancer treatment pathways to be 97 and 99%, respectively. The reason for
non-compliance proved to be either a failure to complete the prescribed care based on
grade II or III toxicity (n=1 breast, 3 prostate) or patient elected discontinuance of care
(n=1 prostate) or the physician chose a higher dose for positive/close margins (n=3
breast).
Conclusion:This study demonstrates that consensus and evidence-based treatment path-
ways can be developed and implemented in a multi-center department of radiation oncol-
ogy. And that for prostate and breast cancer there was a high degree of compliance using
these directives. The development and implementation of these pathways serve as a
key component of our safety program, most notably in our effort to facilitate consistent
decision-making and reducing variation between physicians.
Keywords: radiation oncology, value-based medicine, care pathways, protocols
INTRODUCTION
The correct time to adopt new technology and treatment options
has always posed a clinical challenge. Given the increasing com-
plexity of cancer treatment techniques, there is also potentially
a negative impact on patient safety, treatment effectiveness, and
efficiency of treatment delivery. These concerns have prompted
an effort to standardize our delivery of radiation therapy based
on best practices determined by published evidence and consen-
sus. Treatment pathways and clinical guidelines aimed at creating
more uniform and standard measures of care are increasingly uti-
lized to address the need for care optimization. Clinical guidelines
such as those prepared by the National Comprehensive Cancer
Network (NCCN)1 have been developed as decision trees that
broadly define oncologic care. Nevertheless, for radiation oncol-
ogy, these guidelines fail to provide details that are relevant to the
1http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
field. The Radiation Therapy Oncology Group (RTOG)2 treatment
protocols offer detailed treatment pathways in radiation oncology;
yet, only reflect a small portion of everyday clinical care and are
rarely used outside of clinical trials. Thus, treatment pathways
need to outline and standardize care details that match evidence-
based outcomes and which offer guidance and consistency for the
detailed and obtuse process of radiation planning, delivery, and
clinical management.
The institution of treatment pathways, especially at a large,
multi-center academic practice, faces many challenges. The most
obvious challenge includes physician preference based on individ-
ual training and clinical experience. Even when physicians agree
on a specific treatment protocol, significant variability may still
arise in the delineation of the Clinical Target Volume (CTV) mag-
nitude or relative target location. (Batumalai et al., 2011) Another
2http://www.RTOG.org
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factor subject to variability is the reporting of doses and outcomes
from studies, as highlighted by the recent Quantitative Analysis
of Normal Tissue Effects in the Clinic (QUANTEC)3, making
the task of generating dose-response curves from data formidable
(Emami et al., 1991). While substantial efforts toward standardiz-
ing treatment assessments in regards to toxicity have been made
by the National Cancer Institute toward the Common Terminol-
ogy Criteria for Adverse Events (CTCAE)4 and by the European
Organization for Research and Treatment for Cancer (EORTC) for
late effects using the Late Effects Normal Tissue Task Force subjec-
tive, objective, management, and analytic criteria (LENT-SOMA)
(Pavy et al., 1995) there remains a lack of uniform and consistent
integration of these metrics by the radiation community at large.
This study addresses the process of developing evidence and
consensus-based, outcomes-oriented treatment pathways that
incorporate the standardization of treatment algorithms and
assessments into a large, multi-center academic radiation oncol-
ogy practice. We reviewed our compliance reflecting physician
acceptance and incorporation of the treatment pathways into our
day-to-day clinical practice. Our primary analysis reviews how
commonly used treatment pathways, for prostate cancer and early-
stage breast cancer, comply with dose and fractionation scheme.
Ultimately, adherence to dose constraints may correlate with mor-
bidity and outcomes data. In this way, we hope to assure our
patients of appropriate therapy delivered with recognized and
accepted approaches.
MATERIALS AND METHODS
Starting in 2007, the Department of Radiation Medicine at
North Shore-LIJ Health System began the process of develop-
ing consensus-based treatment pathways based on the Institute
of Medicine (IOM) outline for guideline development5 (Institute
of Medicine Outline for Guideline Development in Appendix).
A Pathways Committee was formed consisting of members
from all disciplines within the department (including radia-
tion oncology physicians, physicists, dosimetrists, therapists, and
nurses), with the stipulation that all members be current employes
of the Health System and not possess any conflicts of interest. The
committee was charged with creating treatment pathways based
on a standard outline and incorporating evidence-based treatment
options to define all aspects of radiation therapy. Allowed avenues
of evidence included recognized national or society guidelines,
results of randomized controlled trials, phase I and II clinical stud-
ies, and current on-going cooperative group trial pathways. The
pathways are broken down by disease site and stage, and include
the treatment pathway, which is composed of details on the pre-
scription, including treatment site, technique, modality, prescribed
dose, daily fraction dose, number of fractions, and treatment
schedule; treatment planning parameters, inclusive of contouring
definitions, and dose constraints to all targets and normal tissue;
and treatment assessments, which include on-treatment nurs-
ing instructions, and survivorship details including a follow-up
3http://www.aapm.org/pubs/QUANTEC.asp
4http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
5www.iom.edu/∼/media/Files/Report%20Files/2011/Clinical-Practice-Guidelines-
We-Can-Trust/Clinical%20Practice%20Guidelines%202011%20Report%20Brief.
pdf
schedule and post treatment testing. An example of a pathway is
provided for external beam radiation therapy for the breast (Exam-
ple of External Beam Radiation Therapy Protocol for Breast Cancer
in Appendix).
Each pathway was then distributed to the faculty and staff
within the Department for feedback, and a second final review
by the committee was performed prior to inclusion in our elec-
tronic medical record (EMR) (MOSAIQ, Elekta). All pathways
are re-reviewed and adapted to ensure they continued to reflect
evolving evidence and clinical issues if they were to arise. After a
treatment pathway and assessment standard has been completed
and approved, a billing guideline is established using Current Pro-
cedural Terminology (CPT)6 that is linked to each Pathway. These
pathways can then be chosen and linked in the EMR for the treat-
ment of any patient and subsequently the compliance of each
pathway can be audited.
The pathways were also re-reviewed in 2010 and updated
based on the recommendations of the QUANTEC (see text foot-
note 3) that summarized dimensional dose/volume/outcome data
for many organs that were defined in terms of normal tissue
dose/volume tolerances (Fowler et al., 1963; Deasy, 2010).
Each physician has latitude to select any treatment pathway
from a library or to write their own treatment prescription for
their patients. The intent is to create treatment pathways that are
applicable to the majority of patients and that may require only
minimal editing. Therefore, the physician still has allowance, albeit
limited; to personalize the patient’s care based on what they believe
is optimal treatment when using a pathway from the library.
Analysis from our EMR for breast and prostate cancer was
performed to assess compliance in incorporating these directives
into our day-to-day clinical practice. For quantitative and compli-
ance analysis, we mined data from our EMR from January 1, 2010
through February 2012 for patients with breast and prostate can-
cer using the CPT code library. Compliance was then determined
by matching the number of fractions given for each prescription
to the chosen treatment pathway for each patient. Non-compliant
patient charts were individually reviewed during routine weekly
chart rounds.
RESULTS
Between 2008 and 2010, a total of 85 treatment pathways were
developed and implemented within the EMR of our depart-
ment (Table 1 and Example of External Beam Radiation Therapy
Protocol for Breast Cancer in Appendix).
Prior to the use of standardized treatment pathways, retrospec-
tive analysis of EMR data revealed that there was significant vari-
ability in the choice of total dose and dose per fraction. Between
2006 and 2008, seven different doses were used to treat the whole
breast for stage I and II breast cancer. A total of 15 different boost
doses were used during the same period. Further analysis of a
period during which the pathways were implemented was per-
formed and identified 155 patients (January 2011–February 2012)
treated with stage I or II cancer of the breast and 294 patients
(January 2010–March 2011) treated for clinically confined cancer
of the prostate. The use of a specific treatment pathway versus
6https://catalog.ama-assn.org/Catalog/cpt/cpt_home.jsp
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Table 1 | Current library of treatment pathways in use at North
Shore-LIJ Health System.
Class Pathway
Breast Breast Canadian tangents supine
Breast Breast Canadian tangents prone
Breast Breast_standard tangents supine
Breast Breast standard tangents prone
Breast Breast tangents nodes and boost
Breast Breast_postmastectomy
Breast Breast RTOG_1005_standard boost
Breast Breast RTOG_1005_concurrent boost
Breast Breast partial breast irradiation
GU Prostate EBRT bat
GU Prostate EBRT calypso
GU Prostate EBRT IGRT
GU Prostate EBRT+brachy
GU Prostate nodes EBRT alone
GU Prostate nodes EBRT+BRACHY
GU Prostate brachytherapy
GU Prostate post_prostatectomy
GU Prostate RTOG 0815 EBRT alone
GU Prostate RTOG 0815 brachy+EBRT
GU Prostate 0924 whole pelvis
GU Prostate 0924 prostate alone
GU Bladder definitive chemort
GU Bladder palliative
GU Seminoma paraaortics
GU Penis definitive chemort
GU Prostate salvage brachytherapy
GYN cervix definitive
GYN CERVIX postop
GYN Endometrial postop
GYN Endometrial hdr_brachy
GYN Endometrial definitive
Head and neck HN_definitive IMRT+ chemo
Head and neck HN definitive IMRT alone
Head and neck HN_postop IMRT
Head and neck HN dahanca
Head and neck Larynx early-stage
CNS Brain GBM RTOG
CNS Brain GBM EORTC
CNS Brain glioma low grade
CNS Brain meningioma_malignant
CNS Brain meningioma atypical
CNS Brain_pituitary
CNS Brain metastatic 3000
CNS Brain metastatic 3750
CNS Brain PCI SCLC
CNS Brain CNS lymphoma
CNS Brain PEDS
CNS Craniospinal
GI Anal chemort
GI Esophagus definitive chemort
GI Gastric post OP chemort
GI Pancreas_definitive chemort
(Continued)
Class Pathway
GI Pancreas neoadj_adjuvant
GI Rectum_preop chemort
GI Liver microspheres
Lung Lung_NSCL chemort
Lung Lung NSCL RT alone
Lung Lung NSCL preop chemort
Lung Lung NSCL postop RT
Lung Lung SCLC chemort
SRS and SBRT SRS AVM
SRS and SBRT SRS_brain metastasis
SRS and SBRT SRS_brain met large
SRS and SBRT SRS_trigeminal_neuraglia
SRS and SBRT SRS_acoustic_schwannoma
SRS and SBRT SBRT_lung central
SRS and SBRT SBRT lung peripheral
SRS and SBRT SBRT_spine cervical
SRS and SBRT SBRT spine thoracic
SRS and SBRT SBRT spine lumbar
SRS and SBRT SBRT prostate
SRS and SBRT SBRT liver
SRS and SBRT SBRT pancreas
Lymphoma Hodgkins_bulky
Lymphoma Hodgkins_low_risk
Lymphoma Non_Hodgkins
Sarcoma Sarcoma
Skin Skin_basal_squamous
Skin Skin_melanoma
Bone Bone metastasis
Bone Heterotopic bone
IVBT 18.4 Gy
IVBT 23.0 Gy
TBI Adult
TBI Protocol
an ad hoc prescription for these diagnoses was 100%. For each of
these diagnoses, the overall compliance for the selection of either
a breast or prostate directive was found to be 97 and 99% respec-
tively (Table 2). The reason for non-compliance proved to be either
a failure to complete the prescribed care based on grade II or III
toxicity (n= 1 breast, 3 prostate) or patient elected discontinuance
of care (n= 1 prostate) or the physician chose a higher dose for
positive/close margins (n= 3 breast).
DISCUSSION
This study demonstrates that consensus and evidence-based treat-
ment pathways can be developed for a multi-center department of
radiation oncology and implemented with high degrees of com-
pliance. Moreover, hurdles such as physician bias and resistance
to conformity can be overcome by offering pathways that have
been rigorously researched and vetted. The utilization of these
treatment pathways serves as a key component of our safety pro-
gram. And while the pathways are not designed to eliminate the
role of physician decision-making nor that of peer review, they do
www.frontiersin.org May 2013 | Volume 3 | Article 105 | 3
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Table 2 | Compliance of prostate and breast cancer therapy.
Prostate pathways Number of
cases
Percent usage (N =292)
January 2010–March 2011
Prostate EBRT 124 42
Prostate EBRT+brachy 25 9
Prostate brachytherapy 84 29
Prostate
post_prostatectomy
30 10
prostate RTOG 0815 EBRT
alone
8 3
Prostate RTOG 0815
brachy+EBRT
12 4
SBRT prostate 5 2
Non-compliant (does not use
any of the above pathways)
4 1
Breast pathways Number of
cases
Percent usage (N =155)
January 2011–February 2012
Breast brachytherapy
(mammosite)
12 8
Breast Canadian tangents
(prone or supine)
57 37
Breast standard tangents
(prone or supine)
58 37
Breast tangents
nodes+boost
6 4
Breast post mastectomy 14 9
Breast
RTOG_1005_standard boost
3 2
Non-compliant (does not use
any of the above pathways)
5 3
serve as a means of creating standard approaches for a specialty
that offers a wide variety of subjective treatment options that can
often lead to misunderstanding and confusion.
Safety in radiation oncology involves many aspects of the care
continuum. Our safety program includes six-sigma mechanics,
quality checklists, and interlocks defined as the “No Fly” policy
(Kapur and Potters, 2012; Potters and Kapur, 2012). Our depart-
ment initiates patient treatments based on timed activities for each
event outlined within a given treatment plan. When a particular
task is completed, it is checked off the quality checklist, which
then triggers the next task to appear on the checklist. This system
ensures that tasks are taking place on time, within the correct time-
frame, and stops are in place so that nothing proceeds beyond an
uncompleted task. Direct input and transparency from all aspects
of the department (including nursing, dosimetry, and physics)
when developing the pathway has allowed for a much better under-
standing of key issues that may be encountered when dealing
with both routine and complex cases and has improved overall
efficiency, compliance and resource utilization. Essentially, these
pathways serve as a bridge between the medical decision-making
process and the technical process of treatment delivery, pro-
viding a working foundation for the entire patient experience.
Implementation of the treatment pathways within the context of
our safety program helps to standardize the types of checklist items
and the process of completion of those items. Furthermore, the
rationale for these pathway is based upon the recommendations
proposed by the Institute for Safe Medical Practices (ISMP)7, a fed-
erally certified non-profit organization devoted to patient safety
in healthcare. According to the ISMP, standardization of care as
outlined by the treatment pathway is ranked third behind Forc-
ing Functions and Computerization in terms of effectiveness for
hazard mitigation, and thus, for increasing patient safety.
The treatment pathways provide the foundation for a physician
to manage a treatment plan that is both evidence and consensus
based. They provide the prescription, which comprises the dose
and fractionation, machine energy, and treatment technique for
that particular treatment as well as detailed instructions on how
to manage the patient during and after treatment. Utilization of
treatment pathways facilitates more consistent decision-making
and reduces variation between physicians in the management of
patients with similar diagnoses. One argument against the creation
and use of treatment pathways is the potential loss of autonomy in
offering patients personalized care. Further, it is argued that physi-
cians prefer to detail treatment based on how they were trained
and on past experience. Nonetheless, we observed a high degree
of compliance attributable to providing physicians with a range
of options that allowed for personalization, yet remained within
our guidelines for best evidence and consensus-based treatment.
Compliance was also driven in part by the collaborative nature
of the directives’ development as well as the safety advantage of
using a care pathway familiar with the department staff. Having
implemented these pathways directly into the EMR allows for the
ease of selecting and optimizing treatment parameters for each
patient. Care pathways created on the fly run the risk of being
treated in a way that is either not communicated effectively to the
rest of the health care team or in a manner that does not keep
with current evidence. Most interestingly, the attempt (by author
LP) to expand the directives to other departments in a collabo-
rative manner with additional input failed, as physicians felt they
would lose their autonomy by the (consensus-based) process and
by using standardized treatment pathways.
The use of these pathways has not obviated the role of peer
review, such as chart rounds. Nevertheless, it has changed chart
rounds by focusing on those cases treated in a manner that dif-
fers from the treatment pathways. These discussions often pro-
vide opportunity to review and consider updates to the current
pathways. Peer review also allows us to explore automated met-
rics that measure conformance in various aspects of treatment
pathway-based care such as from physician, planner/physicist,
nursing, follow-up, and billing. This should ultimately enhance the
value of peer review and provide constant feedback that provides
opportunity to hone the quality of the pathways.
The most recent IOM update of standards for developing trust-
worthy Clinical Practice Guidelines, with which our process for
developing our pathways closely complies, calls for transparency,
management of conflict of interest, creation of a multidisciplinary
group, systematic reviews, evidence rating, articulation, external
review, and updating. In the current study we failed to have an
7https://www.ismp.org/orderforms/reporterrortoismp.asp
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external review. In an effort to further enhance the process and to
explore opportunities for external review, we are currently work-
ing with several other departments, such as medical oncology, on
validation of our created pathways, as well as the possibility of
standardizing care with other partnered institutions. Our inability
to meet the IOM standard for external review is the direct result of
skepticism from other institutions that consensus can be reached
or that it is even meaningful (personal communication LP). Indi-
vidual physicians bring biases from past clinical experience and
more generally from where they trained. Often a physician will
prescribe a treatment solely based on these biases – even if that
treatment has not become the standard of care within the com-
munity. Overcoming this bias within our department itself proved
to be most difficult when attempting to establish consensus on a
given pathway where there was a lack of evidence for the proper
treatment plan. However, our report citing the high rates of com-
pliance in our academic clinic may serve as a catalyst for other
departments to consider pathways as a viable alternative to a more
subjective approach and participate in the process of creating more
universal standards of care. If a more generalized consensus can be
reached across several departments and implemented, this could
have a profound effect on the safe delivery of radiation, especially
since traditional guidelines present appropriateness of treatment,
but often do not offer detailed therapy directives. The training
of physics staff and therapists could become more uniform and
the expectations of clinical care, such as nursing, would be more
clearly defined. This would also have the added benefit of cre-
ating a larger base of patients that would have been treated in
the same way, with the outcomes of these treatments therefore
becoming more meaningful. Clearly we are not the first institu-
tion to have implemented internal treatment pathways, yet our
process of creating and our overall compliance to these path-
ways serves as a model for other departments considering this
change.
These pathways also offer a cost-effective, peer reviewed alter-
native to the guidelines of Radiation Oncology Business Manage-
ment (ROBM) companies. ROBM companies have been increas-
ingly dictating care as an effort to control the “cost of care” as a
value-add to the managed care industry. Their efforts utilize the
granularity of the CPT code process. The “black box” methodol-
ogy of ROBM guideline development is generally framed primarily
with cost containment in mind. Therefore, the focus is on mini-
mally acceptable care standards for any given disease. Furthermore,
the for-profit ROBM pathways are designed with the intent of
managing resource utilization and cost associated with emerging
technologies for radiation therapy – which is in direct contrast
to the development and use of our pathways. As such, the obvi-
ous side effect of the ROBM’s increased market penetration is
the development and mandated use of pathways with the explicit
purpose of mitigating expense on a per-patient basis.
One unintended but key finding in our current study was the
identification of how directives are used based on aggregate care.
Upon institution of our pathways, there was no discussion on
resources or costs associated with the different treatment options
whatsoever – the selection of each pathway was at the discretion
of the attending physician and based solely on selecting an appro-
priate pathway given an individual patient’s characteristics. Our
high percentage use of Canadian fractionation for breast cancer
(which is considered a less expensive option for the treatment of
breast cancer) has been shown to drive down the aggregate cost
of treating the disease – without compromising the quality of
care for each individual patient since each treatment option was
selected solely on the basis of providing the most effective, high-
est quality treatment for each patient. For instance, the average
Medicare payment for breast cancer based on Directive Compli-
ance was $10,888 compared to $14,698 payment for on standard
(long course) treatment. The directive payment is 74% of long
course treatment. Unlike ROBMs that manage individual cases by
limiting resources per patient, the development and use of multi-
ple care pathways does not discriminate the resources needed for
any given patient necessary for evidence-based care, yet also seems
to create an environment that decreases the overall cost of care.
In conclusion, we have developed an approach of directive
development and implementation that demonstrates high degrees
of compliance that also offers cost-effective care. What started
out as, and remains, a key component of our safety program has
afforded our physicians the opportunity to personalize care for
their patients while also being assured that the care they deliver is
both the safest and most effective for a given disease. We hope to
work with other institutions in establishing external validation of
our pathways and hopefully develop consensus that will create the
impetus for transparent, evidence-based radiation therapy.
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APPENDIX
INSTITUTE OF MEDICINE OUTLINE FOR GUIDELINE DEVELOPMENT
1. Establishing transparency
2. Management of conflict of interest
3. Guideline development group composition
4. Clinical practice guideline-systematic review intersection
5. Establishing evidence foundations for and rating strength of recommendations
6. Articulation of recommendations
7. External review
8. Updating
EXAMPLE OF EXTERNAL BEAM RADIATION THERAPY PROTOCOL FOR BREAST CANCER
.BREAST, STANDARD TANGENTS SUPINE
PRESCRIPTION
Rx site: breast _L/_R (CHOOSE LATERALITY)
Technique: 3D conformal
Modality: 6–23 MV
Dose specified: as per plan
Rx dose: 5000 cGy
Fraction dose: 200 cGy
# Fx’s/pattern: 25/once daily
ON TREATMENT
Filming: tangents including entire field prior to first treatment, then weekly alternate medial and lateral tangent (planned field only,
entire field not necessary).
Nanodots Frequency: first day, then weekly, five to six dots total
Nanodots Placement: setup patient to treatment isocenter. Rotate the gantry to 0˚, turn on the field light, and place the dot on the
central axis. Cover with 5 mm bolus.
2nd Rx site: breast boost _L/_R (CHOOSE LATERALITY/OPTIONAL)
Technique: enface
Modality: 6–8 MeV
Dose specified: 90–100%
Rx dose: 1000 cGy
Fraction dose: 200 cGy
# Fx’s/pattern: 5/once daily
ON TREATMENT
Nanodots Frequency: first day, one dot total.
Nanodots Placement: center of electron field. DO NOT cover with bolus.
SIMULATION INSTRUCTIONS:
SUPINE
Preparation: no specific preparation required.
Position: supine on breast board with appropriate angle for upper torso, ipsilateral arm extended above head; contralateral arm at side;
the patient’s midline (medial biangulation tattoo) is set with the X -axis laser at zero.
Devices: breast board, knee pillow, wires, BBs.
Procedures: mark lumpectomy scar and drain sites with wire, place wire at 2 cm below the inframammary margin.
CT scan: scan from sternal notch to 4 cm past inframammary margin.
Tattoos: total four – two medial and lateral BBs at approximate center of treatment plane, approximately 2 cm inferior to inframammary
fold.
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SUPINE BOOST at LIJ using Clarity ultrasound
Preparation: enter patient into the Clarity system.
Prior to CT scan, zero the couch Longitude at the biangulation plane to register the lumpectomy cavity origin.
CT scan: scan entire region as for breast tangents.
Obtain measurement from CT on slice that shows the lumpectomy cavity, from the skin surface down to the chest wall in order to set
gain correctly.
Ultrasound: bring patient/table back to original longitude/zero position.
Remove wire and ultrasound area using steady, light pressure across the scar region.
Send scan to appropriate planning location and to Clarity.
Isocenter/tattoos: The origin sets the biangulation tattoos for the tangents and the boost will be derived from this origin. Same tattoos
for the breast tangents.
PLANNING:
Technique: 3D conformal (forward planning).
Target definition:
MD contour: boost volume, heart for left-sided breast, mark four borders with points as per guidelines below.
Medial: mid-sternum.
Lateral: mid-axillary line.
Superior: base of clavicular head.
Inferior: 2 cm below the inframammary fold.
Boost CTV/PTV: MD will contour the cavity=CTV, then create PTV with 5–10 mm margin, cutout will be made with 5 mm beyond
PTV.
Breast CTV/PTV: defined as 95% isodose line (by planner).
Heart (Left-sided treatment): contours should begin at the level of the bifurcation of the pulmonary artery into left and right branches,
include great vessels, pericardium.
Target goals: dose constraints for planning includes all structures in DVH:
Breast CTV/PTV: D95= 95%
Max dose ≤107%
Boost CTV/PTV: D95= 95%
Max dose ≤115%
Ipsilateral lung: ideal V20Gy ≤15%; acceptable V20Gy ≤20%
Ipsilateral lung: ideal V10Gy ≤35%; acceptable V10Gy ≤40%
Ipsilateral lung: ideal V5Gy ≤50%; acceptable V5Gy ≤55%
Contralateral lung: ideal V5Gy ≤10%; acceptable V5Gy ≤15%
Heart (left-sided treatment): ideal V20Gy ≤5%; acceptable V25Gy ≤5%
Heart (left-sided treatment): ideal V10Gy ≤30%; acceptable V10Gy ≤35%
Heart mean dose: ideal ≤400 cGy; acceptable ≤500 cGy.
NURSING INTERVENTIONS
Consultation/education: document a complete evaluation including physical examination, review of systems, baseline vital signs, and
blood work within 1 month of starting treatment. Complete patient education including simulation, filming, treatment, and possible
side effects and management of these side effects. Review skin care and provide resources for obtaining skin care products.
After consultation: review QCL items needed and schedule items when appropriate, e.g., HCG at simulation, EKG for pacemaker at
first treatment.
On treatment: start skin care treatment on or before day 1. Assess patient and document weekly during OTV and more often when
needed, e.g., escalating side effect, pain management.
Laboratory: HCG at or prior to simulation for premenopausal patients, CBC×1 during treatment.
Completion: on or prior to last treatment, provide patient with written discharge instructions.
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FOLLOW-UP/SURVIVORSHIP
PTE at 1 month: ensure resolution of acute side effects, radiation dermatitis.
Follow-up: every 3–6 months afterward for 2 years, then every 6–12 months, then consider discharge to oncologist/PMD after 5 years.
Mammography annually: document report and order if not done.
Co-management: surgical oncologist, medical oncologist.
CPT CODE SETS: see Documents “Coding Outline.”
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Dose constraints from RTOG 1005 – a Phase III trial of accelerated whole breast irradiation with hypofractionation plus concurrent
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